Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001226644 | SCV001398965 | uncertain significance | Proteasome-associated autoinflammatory syndrome 1 | 2022-09-26 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 245 of the PSMB8 protein (p.Val245Ile). This variant is present in population databases (rs746897143, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with PSMB8-related conditions. ClinVar contains an entry for this variant (Variation ID: 954224). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PSMB8 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genome Diagnostics Laboratory, |
RCV002264235 | SCV002542831 | uncertain significance | Autoinflammatory syndrome | 2022-04-14 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004032582 | SCV005012784 | uncertain significance | Inborn genetic diseases | 2024-01-22 | criteria provided, single submitter | clinical testing | The c.733G>A (p.V245I) alteration is located in exon 5 (coding exon 5) of the PSMB8 gene. This alteration results from a G to A substitution at nucleotide position 733, causing the valine (V) at amino acid position 245 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |